History and prospects of the development of coronary stenting (brief essay)

Cover Page

Cite item

Full Text

Abstract

This article is devoted to the history of the development of coronary stenting, review of modern technologies and perspectives for the further development of this technique.

About the authors

A. I Analeev

Institute of Professional Development

Email: anton-analeev@yandex.ru
ассистент каф. рентгенэндоваскулярных и миниинвазивных методов диагностики и лечения ФГБУ ВПО ИПК 125371, Russian Federation, Moscow, Volokolamskoe sh., d. 91

S. P Semitko

Institute of Professional Development; V.V.Veresaev City Clinical Hospita

Email: semitko@mail.ru
д-р мед. наук, проф., зав. каф. рентгенэндоваскулярных и миниинвазивных методов диагностики и лечения ФГБУ ВПО ИПК, ГБУЗ ГКБ им. В.В.Вересаева 125371, Russian Federation, Moscow, Volokolamskoe sh., d. 91; 127644, Russian Federation, Moscow, ul. Lobnenskaia, d. 10

References

  1. Gruntzig A. Transluminal dilatation of coronary - artery stenosis. Lancet 1978; 1: 263.
  2. Garg S, Serruys P.W. Coronary stents: current status. J Am Coll Cardiol 2010; 56: S1-42.
  3. Bauters C, Meurice T, Hamon M et al. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res 1996; 31: 835-46.
  4. Chandrasekar B, Tanguay J.F. Platelets and restenosis. J Am Coll Cardiol 2000; 35: 555-62.
  5. Clowes A.W, Reidy M.A, Clowes M.M. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 49: 208-15.
  6. Yoshida Y, Mitsumata M, Ling G et al. Migration of medial smooth muscle cells to the intima after balloon injury. Ann NY Acad Sci 1997; 811: 459-70.
  7. Bennett M.R. In - stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003; 89: 218-24.
  8. Sigwart U, Puel J, Mirkovitch V et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701-6.
  9. De Feyter P.J, De Jaegere P.P, Serruys P.W. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643-51.
  10. Serruys P.W, Strauss B.H, Beatt K.J et al. Angiographic follow - up after placement of a selfexpanding coronary - artery stent. N Engl J Med 1991; 324: 13-7.
  11. Serruys P.W, De Jaegere P, Kiemeneij F et al. A comparison of balloon - expandable - stent implantation with balloon angioplasty in patients with coronary artery disease. BENESTENT study group. N Engl J Med 1994; 331: 489-95.
  12. Fischman D.L, Leon M.B, Baim D.S et al. A randomized comparison of coronary - stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 1994; 331: 496-501.
  13. Hoffmann R, Mintz G.S, Dussaillant G.R et al. Patterns and mechanisms of in - stent restenosis. A serial intravascular ultrasound study. Circulation 1996; 94: 1247-54.
  14. Chen M.S, John J.M, Chew D.P et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260-4.
  15. Morice M.C, Serruys P.W, Sousa J.E et al. A randomized comparison of a sirolimus - eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
  16. Moses J.W, Leon M.B, Popma J.J et al. Sirolimus - eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
  17. Stone G.W, Ellis S.G, Cox D.A et al. A polymer - based, paclitaxel - eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
  18. Poon M, Marx S.O, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277-83.
  19. Axel D.I, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-45.
  20. Abizaid A. Sirolimus - eluting coronary stents: a review. Vasc Health Risk Manag 2007; 3: 191-201.
  21. Mc Fadden E.P, Stabile E, Regar E et al. Late thrombosis in drug - eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-21.
  22. Nordmann A.J, Briel M, Bucher H.C. Mortality in randomized controlled trials comparing drug - eluting vs. bare metal stents in coronary artery disease: a meta - analysis. Eur Heart J 2006; 27: 2784-814.
  23. Camenzind E, Steg P.G, Wijns W. Stent thrombosis late after implantation of first - generation drug - eluting stents: a cause for concern. Circulation 2007; 115: 1440-55. Discussion 1455.
  24. Laskey W.K, Yancy C.W, Maisel W.H. Thrombosis in coronary drug - eluting stents: report from the meeting of the circulatory system medical devices advisory panel of the food and drug administration center for devices and radiologic health, December 7-8, 2006. Circulation 2007; 115: 2352-7.
  25. Schomig A, Neumann F.J, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary - artery stents. N Engl J Med 1996; 334: 1084-9.
  26. Mehta S.R, Yusuf S, Peters R.J et al. Effects of pretreatment with clopidogrel and aspirin followed by long - term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
  27. Morton A.C, Crossman D, Gunn J. The influence of physical stent parameters upon restenosis. Pathol Biol (Paris) 2004; 52: 196-205.
  28. Amin A.P, Spertus J.A, Cohen D.J et al. Use of drug - eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med 2012; 172: 1145-52.
  29. Fajadet J, Wijns W, Laarman G.J et al. Randomized, double - blind, multicenter study of the endeavor zotarolimus - eluting phosphorylcholine - encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR-II trial. Circulation 2006; 114: 798-806.
  30. Serruys P.W, Silber S, Garg S et al. Comparison of zotarolimus - eluting and everolimus - eluting coronary stents. N Engl J Med 2010; 363: 136-46.
  31. Stone G.W, Midei M, Newman W et al. Comparison of an everolimus - eluting stent and a paclitaxel - eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299: 1903-13.
  32. Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug - eluting and bare - metal stents: evidence from a comprehensive network meta - analysis. Lancet 2012; 379: 1393-402.
  33. Windecker S, Serruys P.W, Wandel S et al. Biolimus - eluting stent with biodegradable polymer versus sirolimus - eluting stent with durable polymer for coronary revascularization (LEADERS): a randomised non - inferiority trial. Lancet 2008; 372: 1163-73.
  34. Regar E, Sianos G, Serruys P.W. Stent development and local drug delivery. Br Med Bull 2001; 59: 227-48.
  35. Park K.W, Kang S.H, Velders M.A et al. Safety and efficacy of everolimus - versus sirolimus - eluting stents: a systematic review and meta - analysis of 11 randomized trials. Am Heart J 2013; 165: 241-50 e244.
  36. Greenhalgh J, Hockenhull J, Rao N et al. Drug - eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010; 12: CD004587.
  37. Pfisterer M, Brunner-La Rocca H.P, Rickenbacher P et al. Long - term benefit - risk balance of drug - eluting vs. Bare - metal stents in daily practice: does stent diameter matter? Three - year follow - up of BASKET. Eur Heart J 2009; 30: 16-24.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies